IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
Portfolio Pulse from
IN8bio presented positive Phase 1 data for its gamma-delta T cell therapy, INB-100, at the TCT 2025, showing promise in reducing post-transplant relapse in high-risk AML patients.
February 14, 2025 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
IN8bio's presentation of positive Phase 1 data for INB-100 at TCT 2025 highlights the therapy's potential in reducing post-transplant relapse in high-risk AML patients, which could enhance investor confidence and positively impact stock prices.
The positive Phase 1 data for INB-100 presented at a major conference like TCT 2025 suggests significant progress in IN8bio's product pipeline, likely boosting investor sentiment and stock prices in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100